miR-155 meets the JAK/STAT pathway.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Elucidating the preventive and therapeutic effects of cardiac telocytes paracrine microRNAs on ischemic heart disease.Frontiers in cardiovascular medicine · 2025
   Article
2. Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.International journal of molecular sciences · 2021
   Review
3. The MicroRNA miR-155 Is Essential in Fibrosis.Non-coding RNA · 2019
   Review
4. Inhibition of microRNA-155 alleviates lipopolysaccharide-induced kidney injury in mice.International journal of clinical and experimental pathology · 2017
   Article
5. miRNA in Macrophage Development and Function.Antioxidants & redox signaling · 2016
   Review
6. Down-regulation of hsa-miR-1264 contributes to DNMT1-mediated silencing of SOCS3.Molecular biology reports · 2015
   Article

Corrections and comments

• Comment on
  STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as